Education
About Us
Working with TipRanks
Follow Us
Passage Bio (PASG)
NASDAQ:PASG
PASG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.12 - $26.60
Previous CloseN/A
Volume182.24K
Average Volume (3M)59.69K
Market Cap
$22.19M
Enterprise Value-$7.52M
Total Cash (Recent Filing)$57.63M
Total Debt (Recent Filing)$24.73M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Nov 18, 2025EPS Estimate
-2.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.96
Shares Outstanding3,120,295
10 Day Avg. Volume21,587
30 Day Avg. Volume59,690
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.34
Enterprise Value/Revenue-2.34
Enterprise Value/Gross Profit-18.58
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$59.25Price Target Upside732.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Biomarker ConsistencyCSF PGRN levels in the first Dose 2 patient already approached the upper limit of the healthy adult reference range at 30-days, showing promise for the therapy.
Regulatory ProgressBoth the Independent Data Monitoring Committee and the FDA have agreed that the next patient can be dosed as planned with additional safety monitoring.
Therapeutic PotentialThe clinical update supports PBFT02 to be a promising therapy for FTD-GRN at Dose 2, and additional safety and biomarker data from more Dose 2 patients should support discussion with the FDA on the regulatory pathway for PBFT02.
Bears Say
Market PenetrationThe peak penetration assumption is decreased from 25% to 15% due to the evolving competitive landscape.
Safety ConcernsThe emergence of a new SAE (pulmonary embolism) in Patient 8 following treatment with Dose 2 has raised safety concerns.
Valuation ImpactThe risk-adjusted valuation of PBFT02 decreased significantly from ~$1B to $283M, impacting the overall valuation.
Passage Bio News
PASG FAQ
What was Passage Bio’s price range in the past 12 months?
Passage Bio lowest stock price was $5.12 and its highest was $26.60 in the past 12 months.
What is Passage Bio’s market cap?
Passage Bio’s market cap is $22.19M.
When is Passage Bio’s upcoming earnings report date?
Passage Bio’s upcoming earnings report date is Nov 18, 2025 which is in 73 days.
How were Passage Bio’s earnings last quarter?
Passage Bio released its earnings results on Aug 12, 2025. The company reported -$2.96 earnings per share for the quarter, beating the consensus estimate of -$4.04 by $1.08.
Is Passage Bio overvalued?
According to Wall Street analysts Passage Bio’s price is currently Undervalued.
Does Passage Bio pay dividends?
Passage Bio does not currently pay dividends.
What is Passage Bio’s EPS estimate?
Passage Bio’s EPS estimate is -2.81.
How many shares outstanding does Passage Bio have?
Passage Bio has 3,120,295 shares outstanding.
What happened to Passage Bio’s price movement after its last earnings report?
Passage Bio reported an EPS of -$2.96 in its last earnings report, beating expectations of -$4.04. Following the earnings report the stock price went down -4.915%.
Which hedge fund is a major shareholder of Passage Bio?
Currently, no hedge funds are holding shares in PASG
Passage Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.25 (732.16% Upside)
$59.25 (732.16% Upside)
Blogger Sentiment
Bullish
PASG Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 59.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $536.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.18%
12-Months-Change
Fundamentals
Return on Equity
-88.27%
Trailing 12-Months
Asset Growth
-36.84%
Trailing 12-Months
Company Description
Passage Bio
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
PASG Stock 12 Month Forecast
Average Price Target
$59.25
▲(732.16% Upside)
Technical Analysis
Tempest Therapeutics
―
Chemomab Therapeutics
―
Annovis Bio
―
Generation Bio
―
Cognition Therapeutics
―
Ownership Overview
26.55% Insiders
4.94% Mutual Funds
<0.01% Other Institutional Investors
65.10% Public Companies and
Individual Investors